Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish

2 hours ago 2

Jonathan Ponciano, The Motley Fool

Wed, March 11, 2026 astatine 12:08 PM CDT 4 min read

On February 17, 2026, Alpine Global Management disclosed a merchantability of 127,039 shares of Immunovant (NASDAQ:IMVT), with an estimated transaction worth of $2.83 cardinal based connected quarterly mean pricing.

According to a filing with the Securities and Exchange Commission dated February 17, 2026, Alpine Global Management reduced its presumption successful Immunovant by 127,039 shares during the 4th fourth of 2025. The estimated transaction worth was $2.83 million, calculated utilizing the quarterly mean stock price. The fund’s quarter-end valuation for this presumption decreased by $22.36 million, a fig that includes some trading enactment and marketplace terms movements.

This was a sale, leaving Immunovant astatine 11.4% of Alpine’s 13F AUM aft the quarter.
Top holdings aft the filing:
- NASDAQ:IMVT: $66.77 cardinal (12.5% of AUM)
- NASDAQ:RIVN: $51.80 cardinal (9.7% of AUM)
- NYSE:ACHR: $35.17 cardinal (6.6% of AUM)
- NYSE:CVNA: $18.82 cardinal (3.5% of AUM)
- NYSE:ARES: $11.07 cardinal (2.1% of AUM)
As of February 17, 2026, Immunovant shares were priced astatine $26.28, up 26.2% implicit the erstwhile twelvemonth and outperforming the S&P 500 by 17.35 percent points.

Metric

Value

Market Capitalization	$5.35 billion
Net Income (TTM)	($464.20 million)
Price (as of marketplace adjacent February 17, 2026)	$26.28

Immunovant develops monoclonal antibody therapeutics targeting autoimmune diseases.
The steadfast operates a clinical-stage biopharmaceutical model, generating worth done the advancement of proprietary cause candidates toward regulatory support and imaginable commercialization.
It targets patients with autoimmune disorders specified arsenic myasthenia gravis, thyroid oculus disease, and lukewarm autoimmune hemolytic anemia, with healthcare providers and payers arsenic superior stakeholders.

Immunovant, Inc. is simply a clinical-stage biotechnology institution focused connected processing innovative antibody therapies for autoimmune diseases. The institution leverages a targeted attack with its pb asset, batoclimab, aiming to code important unmet aesculapian needs successful specialty indications.

With a robust pipeline and a specialized absorption connected autoimmune conditions, Immunovant seeks to found a competitory presumption successful the biopharmaceutical scenery done objective advancement and imaginable aboriginal commercialization.

Immunovant remains the largest presumption successful this portfolio contempt the fourth-quarter trim, accounting for much than 11% of reported assets. That unsocial suggests condemnation has not disappeared here. Instead, the determination looks much similar an effort to rebalance aft a beardown tally successful the stock.

The institution continues to beforehand batoclimab and different FcRn inhibitors targeting autoimmune diseases specified arsenic myasthenia gravis and thyroid oculus disease, areas wherever caller therapies could bid important pricing powerfulness if objective trials succeed. For now, however, Immunovant remains firmly successful the improvement stage, meaning the concern lawsuit hinges mostly connected objective milestones alternatively than existent revenue. The steadfast anticipates sharing topline information from its 2 Phase 3 studies for batoclimab successful the archetypal fractional of this year.

Against that backdrop, a humble simplification makes sense. The money inactive maintains important vulnerability portion freeing up superior for different high-growth names successful its portfolio, including electrical conveyance shaper Rivian and aerospace startup Archer Aviation.

Read Entire Article